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Abstract: 
In the early neonatal period activation of GABAB receptors attenuates calcium 
current through N-type calcium channels while enhancing current through L-
type calcium channels in rat hippocampal neurons. The attenuation of N-type 
calcium current has been previously demonstrated to occur through direct 
interactions of the βγ subunits of Gi/o G-proteins, but the signal transduction 
pathway for the enhancement of L-type calcium channels in mammalian 
neurons remains unknown. In the present study, calcium currents were 
elicited in acute cultures from postnatal day 6–8 rat hippocampi in the 
presence of various modulators of protein kinase A (PKA) and protein kinase 
C (PKC) pathways. Overnight treatment with an inhibitor of Gi/o (pertussis 
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toxin, 200 ng/ml) abolished the attenuation of calcium current by the GABAB 
agonist, baclofen (10 μM) with no effect on the enhancement of calcium 
current. These data indicate that while the attenuation of N-type calcium 
current is mediated by the Gi/o subtype of G-protein, the enhancement of L-
type calcium current requires activation of a different G-protein. The 
enhancement of the sustained component of calcium current by baclofen was 
blocked by PKC inhibitors, GF-109203X (500 nM), chelerythrine chloride (5 
μM), and PKC fragment 19–36 (2 μM) and mimicked by the PKC activator 
phorbol-12-myristate-13-acetate (1 μM). The enhancement of the sustained 
component of calcium current was blocked by PKA inhibitors H-89 (1 μM) and 
PKA fragment 6–22 (500 nM) but not Rp-cAMPS (30 μM) and it was not 
mimicked by the PKA activator, 8-Br-cAMP (500 μM – 1 mM). The data 
suggest that activation of PKC alone is sufficient to enhance L-type calcium 
current but that PKA may also be involved in the GABAB receptor mediated 
effect. 
Keywords: L-type calcium channel, hippocampus, GABAB receptor, protein 
kinase C, protein kinase A, G-protein. 
L-type calcium channels play a large role in the function of both 
cardiac and skeletal muscle. Thus, many investigators have 
concentrated on studying the regulation of L-type calcium channels in 
muscle tissue, particularly cardiac muscle (for review see Catterall, 
2000). Most of these physiological studies have categorized current as 
L-type without attributing it to one of the four specific isoforms of L-
type calcium channels that have been sequenced (Catterall, et al., 
2005). Since not all isoforms of L-type channels are expressed in all 
tissues, the tissue type often gives a good indication of the isoform 
responsible for the current. For example, Cav1.1 is only expressed in 
skeletal muscle and Cav1.2 is the primary type of L-type channel 
expressed in healthy, adult cardiac tissue. Thus, the studies on 
regulation of L-type calcium channels in skeletal and cardiac muscle 
provide evidence that Cav1.1 and Cav1.2 are regulated by 
phosphorylation. However, these studies on native tissue do not 
provide any information on molecular sequencing. Much less is known 
about the regulation of L-type channels in neurons, which mainly 
consist of Cav1.2 and Cav1.3. The protein sequences of these channels 
demonstrate consensus sequences for a variety of protein kinases 
(Obenauer et al., 2003), suggesting that phosphorylation may be 
involved in their regulation. Regulation of other voltage-dependent 
calcium channels such as N-type (Cav2.2) and P/Q-type (Cav2.1) 
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calcium channels by neurotransmitters and phosphorylation has been 
well studied in neurons (for review see Dolphin, 2003). 
One common neurotransmitter regulating neuronal activity is γ-
amino butyric acid (GABA), either directly through ionotropic GABAA 
receptors or indirectly through metabotropic GABAB receptor 
modulation of ion channels. Upon GABAB receptor activation, neuronal 
calcium channels can be directly regulated by either Gα or Gβγ 
subunits or they can be indirectly regulated by G-proteins through 
second messenger systems (for review see Catterall, 2000; Dolphin, 
2003; Tedford and Zamponi, 2006). We have previously demonstrated 
that GABAB receptor activation can lead to an attenuation of N-type 
calcium current and the enhancement of L-type calcium current in 
hippocampal cultures obtained from neonatal rat pups (Carter and 
Mynlieff, 2004; Bray and Mynlieff, 2009). The variety of responses 
seen in primary hippocampal cultures is likely due to the heterogeneity 
of the neuron types present. It is possible that the enhancement of 
calcium current by GABAB receptors is only present in a particular 
subset of cells. Current through N-type channels is primarily involved 
in neurotransmitter release, and therefore modulation of this current 
by presynaptic receptors is likely to be involved in decreasing 
neurotransmitter release (Hirata et al., 1995; Doze et al., 1995; 
Takahashi et al., 1998). L-type calcium channels are located on the 
soma and dendrites of neurons and thus current through L-type 
channels regulates many processes including enzymatic activity, 
excitability, and gene expression (for review see Lipscombe, 2004; 
Pinato et al., 2009). For example, in neonatal hippocampus calcium 
influx through L-type calcium channels contributes to the regulation of 
expression of the K+Cl− co-transporter (Bray and Mynlieff, 2009). It is 
well known that the inhibition of N-type current by GABAB receptor 
activation in mammalian neurons is mediated by Gβγ subunits from 
the Gi/o protein family, which are sensitive to pertussis toxin (PTX; 
Kleuss et al., 1991; Ikeda et al., 1996; Kajikawa et al., 2001; for 
review see Tedford and Zamponi, 2006). However, the signal 
transduction pathway involved in the enhancement of L-type current 
by GABAB receptors in mammalian neurons is unknown. 
In addition to direct effects of Gβγ subunits on calcium 
channels, activation of G-proteins can lead to activation of kinases, 
which can modulate channel activity as well. L-type channels have 
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several consensus sites for phosphorylation by protein kinase C (PKC) 
and protein kinase A (PKA; Obenauer et al., 2003). GABAB receptor 
activation of PKC and PKA has been shown to enhance L-type calcium 
current in a subset of salamander retinal neurons (Shen and 
Slaughter, 1999). It is not clear that the same signal pathway would 
be utilized in the rat hippocampus. Differences in amphibian versus 
mammalian receptors and channels as well as differences in the retina 
versus hippocampus may cause variation in the signaling pathway. For 
example, in mammalian retinal cells, Cav1.3 and Cav1.4 are the 
primary isoforms of L-type channels expressed (Xu et al., 2002; Ko et 
al., 2007). However, in mammalian hippocampus, Cav1.2 and Cav1.3 
are the primary isoforms of L-type channels expressed and their 
individual expression patterns differ throughout development (Nuñez 
and McCarthy, 2007; Schlick et al., 2010; M. Mynlieff, unpublished 
observations). The different isoforms of L-type calcium channels have 
different phosphorylation consensus sites within their sequences 
(Obenauer et al., 2003; http://scansite.mit.edu) and are thus likely to 
be regulated by different kinases. It has also been demonstrated that 
activation of PKC can enhance L-type calcium current in rat 
hippocampal neurons (Doerner and Alger, 1992). However, this 
response was not directly linked to GABAB receptors. 
The current study was designed to investigate the involvement 
of PKC and PKA in GABAB receptor modulation of L-type calcium 
channels within the neonatal rat hippocampus. Although activation of 
PKC has been shown to enhance L-type calcium current within the 
hippocampus, this is the first study to directly investigate the potential 
role of PKC in GABAB receptor mediated enhancement of L-type 
current in mammalian hippocampus. Electrophysiological experiments 
were performed on cultured hippocampal neurons in the presence and 
absence of several PKC and PKA antagonists, as well as agonists for 
both types of kinases to determine their involvement in the signaling 
pathway of GABAB receptor activation and the subsequent 
enhancement of L-type current. 
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Section 2 – EXPERIMENTAL PROCEDURES 
2.1 Isolation of Hippocampal Neurons 
All animal protocols were approved by the Marquette University 
Institutional Animal Care and Use Committee and followed the 
guidelines set forth by the U.S. Public Health Service. Hippocampal 
neurons were isolated from 6–8 day old Sprague-Dawley rat pups as 
published previously (Mynlieff, 1997). Briefly, the animals were 
anesthetized with CO2 and sacrificed by decapitation. The head was 
immersed in 70% ethanol for several minutes for decontamination and 
rinsed in sterile rodent Ringer’s solution with glucose (146 mM NaCl, 5 
mM KCl, 2 mMCaCl2, 1 mM MgCl2, 10 mM HEPES, 11 mM D-glucose, 
pH 7.4 with NaOH). The hippocampi were dissected from the brain 
using sterile technique in oxygenated, cold (~5°C), rodent Ringer’s 
solution with glucose. For all experiments dissections were restricted 
to the superior region of the hippocampus (excluding the dentate 
gyrus) to minimize the heterogeneity of cell types within the cultures. 
The tissue was placed in PIPES-buffered saline (120 mM NaCl, 5 mM 
KCl, 1 mM CaCl2, 1 mM MgCl2, 25 mM D-glucose, 20 mM piperazine-N, 
N’-bis[2-ethanesulfonic acid], pH 7.0 with NaOH) and sliced into ~1 
mm3 sections. The tissue was incubated in 1 ml of 0.5% Trypsin XI 
and 0.01% DNase I (Sigma-Aldrich, St. Louis, MO) in PIPES-buffered 
saline at room temperature for 30 minutes with 100% oxygen blowing 
over the solution. This incubation was followed by 60 minutes at 35°C 
under continuous oxygen. The tissue was rinsed with 1 ml trypsin 
inhibitor (1 mg/ml trypsin inhibitor, Type II-O: chicken egg white and 
1 mg/ml bovine serum albumin; Sigma-Aldrich, St. Louis, MO) in 
rodent Ringer’s solution. The tissue was rinsed again with 1 ml 
Neurobasal-A growth medium (Invitrogen, Carlsbad, CA) fortified with 
B27 supplement, 0.5 mM glutamine, and 0.02 mg/ml gentamicin and 
triturated with a fire-polished Pasteur pipette in fresh growth medium. 
The cell suspension was plated onto the center of poly-L-lysine coated 
dishes (1 mg/ml, MW 38,500 – 60,000; Sigma-Aldrich, St. Louis, MO). 
The cultures were maintained at 37°C in a 5% CO2 water-jacketed 
incubator. 
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2.2 Electrophysiology 
Calcium currents were measured using whole-cell patch clamp 
recording in voltage clamp mode. Data were collected using a Dagan 
3900A patch clamp amplifier (Dagan Corporation, Minneapolis, MN) 
linked to a computer with a Digidata 1322 data acquisition system and 
pCLAMP 9.0 software (Molecular Devices, Sunnyvale, CA). All 
electrophysiological experiments were performed at room temperature 
20–24 hours following dissociation, which allowed the cells time to 
recover from enzymatic dissociation and adhere to the bottom of the 
dish (Mynlieff, 1997). Recording electrodes (3–7 MΩ) were made from 
borosilicate glass capillaries on a Flaming/Brown Micropipette Puller 
model P-87 (Sutter Instrument Co., Novato, CA). The internal solution 
used to fill the patch electrodes contained 140 mM Cs-aspartate, 5 mM 
MgCl2, 10 mM Cs2EGTA, 10 mM HEPES, 2 mM ATP-Na2, and 0.1 mM 
GTP (pH of 7.4 with CsOH and osmolarity between 310–320 mOsm). 
The external solution used for calcium current measurements 
contained 10 mM CaCl2, 145 mM TEACl, 10 mM HEPES, and 1 μM 
tetrodotoxin (Sigma-Aldrich, St. Louis, MO) to block Na+ currents (pH 
of 7.4 with CsOH and osmolarity between 300–310 mOsm). The cells 
were held at −80 mV and depolarized with a 300 ms pulse to +10 mV. 
Whole-cell currents were electronically filtered at 1 kHz and digitized at 
2 kHz. Linear components of leak current were subtracted post-hoc by 
the passive resistance protocol in pClamp 9.0. 
(RS)-baclofen (Tocris, Ellisville, MO) and 8-Bromoadenosine 3′, 
5′-cyclic monophosphate (8-Br-cAMP; Sigma-Aldrich, St. Louis, MO) 
were directly dissolved in the external calcium solution. GF-109203X 
(AG Scientific, INC., San Diego, CA) and phorbol-12-myristate-13-
acetate (PMA, Calbiochem, La Jolla, CA) were dissolved in dimethyl 
sulfoxide (DMSO) at 1000 – 5000 fold the final concentration. Rp-
cAMPS triethylammonium salt hydrate, H-89 dihydrochloride hydrate, 
protein kinase A inhibitor fragment 6–22 amide, and chelerythrine 
chloride (Sigma-Aldrich, St. Louis, MO) were dissolved in distilled 
water at 333 – 10,000 fold the final concentration. All concentrated 
stock solutions of the drugs were stored at −20°C until use for up to 
two months. Most of these compounds were diluted to their final 
concentration in the external calcium solution on the day of use. 
Kinase inhibitors dissolved in the external solution were bath applied 
for approximately 5–10 minutes prior to activation of GABAB receptors 
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by baclofen as well as being included in the baclofen solution itself. 
Baclofen and kinase activators dissolved in the external calcium 
solution were applied to cells using a U-tube delivery system, 
constructed with PE-10 polyethylene tubing housed in a piece of glass 
tubing, which allowed for quick application and washout of compounds 
that were gravity fed onto the cell and removed by vacuum suction. A 
blue dye, Fast Green FCF (Sigma-Aldrich, St. Louis, MO), was added to 
the drug solution to visualize application of the drug onto the cell and 
to ensure complete washout of the drug off the cell. Protein Kinase A 
fragment 6–22 was included in the internal solution. Protein kinase C 
fragment 19–36 (Sigma-Aldrich, St. Louis, MO) was dissolved in 1% 
acetic acid and included in the internal solution producing minimal 
change in the pH of the internal solution (<0.01). PTX (Sigma-Aldrich, 
St. Louis, MO) was dissolved in distilled water at 500 fold the final 
concentration with bovine serum albumin (4 mg/ml) added for 
stabilization. Cultures were exposed to 200 ng/ml PTX for a minimum 
of 16 hours starting two hours after dissociation. 
2.3 Data Analysis and Statistics 
For analysis, the magnitudes of the currents in response to a 10 
mV depolarizing pulse were plotted as a scatter graph vs. time. The 
linear regression and 95% confidence intervals were determined for 
the control current data points and were used to determine the effect 
of application of 10 μM baclofen on calcium current amplitude as 
described in Carter and Mynlieff (2004; see also Fig. 2). The percent 
change with baclofen application was determined by comparison to the 
regression line. The cells were grouped according to whether baclofen 
application caused a deviation in the magnitude of the calcium current 
when compared to the linear regression line determined by the control 
data. The change in current magnitude was considered significant if it 
fell outside the 95% confidence interval. If the current with baclofen 
application fell above the 95% confidence interval the cells were 
grouped as demonstrating an increase in current and if it fell below the 
95% confidence interval the cells were grouped as demonstrating a 
decrease in current. In the cells where the current with baclofen 
application fell within the 95% confidence interval, the cells were 
grouped together as demonstrating no change. 
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Figure 2 Illustration of baclofen effects on whole-cell calcium currents in 
hippocampal neurons. Calcium currents were elicited by a 300 ms depolarizing pulse 
to +10 mV from a holding potential of −80 mV. The currents in A and B demonstrate 
an attenuation with 10 μM baclofen application. The currents in C and D demonstrate 
an enhancement of current with 10 μM baclofen application. For the graphs in B and 
D, the amplitude of the sustained current at the end of the 300 ms pulse were 
measured and plotted over time. The control currents (circles) were fit with a linear 
regression and a 95% confidence interval. Currents in the presence of 10 μM baclofen 
(triangles) were compared to the linear regression line. Scale bars in A and C are 100 
pA and 50 ms. 
Data were organized in contingency tables and a chi-square test 
was used to determine whether the distribution of the responses to 
baclofen (increase, decrease, and no change) varied in the absence or 
presence of various kinase inhibitors or activators. If the chi-square 
test demonstrated significance, pairwise comparisons were made using 
a Fisher’s exact test. 
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Section 3 - RESULTS 
3.1 The enhancement of calcium current by GABAB 
receptors is still observed in the presence of PTX 
Since one of the most common mechanisms of channel 
modulation by GABAB receptor activation occurs through direct 
modulation by a Gi/o protein, the first experiment performed was 
overnight treatment of hippocampal cultures obtained from 7 day old 
rat pups with PTX to inactivate Gi/o proteins by ADP-ribosylation. PTX 
(200 ng/ml) was added to the cultures two hours after dissociation. 
The effect of 10 μM baclofen on peak calcium current, activated by a 
depolarization to +10 mV, was measured the following day in cells 
treated with PTX and compared to cells without PTX treatment. The 
distribution of the responses (percent cells demonstrating a decrease, 
increase, and no change in peak current) differed in cultures that were 
treated with PTX in comparison to non-treated cultures (P = 0.009 
using a Chi-square). Previous pharmacological experiments in our 
laboratory clearly demonstrated that the attenuation of current was 
due to attenuation of N-type current and the enhancement of current 
was due to enhancement of L-type current (Carter and Mynlieff, 
2004). In cultures that were not treated with PTX, 33.3% of cells 
demonstrated a decrease, 38.5% of cells demonstrated no change, 
and 28.2% of cells demonstrated an increase in peak calcium current 
in response to 10 μM baclofen (N=39). In cultures that were treated 
with PTX, no cells demonstrated a decrease, 73.7% of cells 
demonstrated no change, and 26.3% of cells demonstrated an 
increase in peak calcium current in response to 10 μM baclofen 
(N=19). Enhancement of calcium current in response to 10 μM 
baclofen was still seen in cells treated with PTX, which suggests that 
enhancement of L-type calcium current is not mediated by a PTX 
sensitive G-protein (Fig. 1). However, it was demonstrated that the 
inhibition of N-type calcium current by GABAB receptors in the neonatal 
rat hippocampus is mediated through a Gi/o protein, because following 
PTX treatment no cells demonstrated inhibition of their current (P = 
0.005 using a Fisher’s Exact test for pairwise comparisons). The 
average enhancement of the peak current in response to baclofen was 
very similar with (22.9 ± 4.0, N=5) or without (18.6 ± 3.1, N=11) PTX 
pretreatment. 
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Figure 1 Effect of PTX on the baclofen responses in hippocampal neurons. The 
peak component of calcium current was measured at the beginning of a 300 ms 
depolarizing pulse to +10 mV from a holding potential of −80 mV. Cells were classified 
as demonstrating a decrease (black bar), no change (light gray bar), or an increase 
(dark gray bar) in response to 10 μM baclofen. Data were collected from 39 control 
cells and 19 cells in the presence of PTX (200 ng/ml, P = 0.009 using a Chi-square). 
Pairwise comparisons were done with a Fisher’s Exact Test. * indicates a statistically 
significant difference. 
3.2 Hippocampal neurons in culture demonstrate a 
variety of responses to GABAB receptor activation 
For all PKC and PKA antagonists and agonists, the sustained 
component of the current was analyzed to maximize the contribution 
of L-type calcium current. The peak current is a combination of several 
different types of calcium current, which can hamper the interpretation 
of these data. Since L-type calcium channels exhibit slow inactivation 
kinetics, the sustained current component at the end of the 300 ms 
depolarization pulse to +10 mV was measured to minimize the 
contribution of T-type, N-type, P/Q-type, and R-type calcium current 
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while maximizing the contribution of L-type calcium current to the total 
measurement. Previous studies in which nimodipine, an L-type calcium 
channel antagonist, blocked the ability of baclofen to facilitate 
sustained current confirmed that the facilitatory effect of GABAB 
receptor activation on calcium currents was entirely mediated through 
L-type channels (Carter and Mynlieff, 2004). Control experiments were 
performed on cultures obtained from 6–8 day old rat pups for 
comparison to currents recorded in the presence of various antagonists 
or agonists. Fig. 2 illustrates how the currents were analyzed for 
classification of the responses. The amplitude of the sustained current 
in the presence of baclofen was compared to a linear regression line 
determined by data points collected in the absence of baclofen as 
described in the methods. The cell in fig. 2A and 2B demonstrated a 
decrease in voltage-dependent current when baclofen (10 μM) was 
applied while the cell in fig. 2C and 2D demonstrated an increase in 
voltage-dependent calcium current when baclofen was applied. The 
distribution of cells demonstrating a decrease, an increase, and no 
change in the sustained component of high voltage-activated calcium 
current in response to 10 μM baclofen was very similar to the 
responses we previously measured in cultures obtained from day 7 rat 
pups for the PTX studies. 34.1% of the cells demonstrated a decrease, 
36.4% demonstrated an increase, and 29.5% demonstrated no change 
in the sustained component in response to baclofen (N=44). The 
average magnitudes of the changes in current are given in Table 1. 
 
Table 1 Percent change in sustained current magnitude with GABAB receptor 
activation. 
The sustained component of calcium current was measured at the end of a 300 ms 
depolarization to +10 mV from a holding potential of −80 mV in 44 cells. Control 
currents were measured both before and after baclofen application and a linear 
regression was fit to the data to account for run-up or run-down of the currents with a 
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95% confidence interval (as shown in fig. 2B and 2C). A change in current magnitude 
was considered significant if it fell outside the 95% confidence interval. To calculate 
the percent change, the actual magnitude of current in the presence of baclofen (10 
μM) was compared to the value of the linear regression at that time point. Data are 
expressed as mean ± sem. 
3.3 PKC inhibitors block the ability of baclofen to 
enhance sustained current 
It is well documented that voltage-dependent calcium currents 
run-down or run-up in recordings made from cultured cells, which 
makes the ability to hold a cell through numerous drug applications 
and washes limited. Therefore, all experiments with kinase inhibitors 
and activators were carried out as population studies, comparing the 
distribution of responses in the presence and absence of each 
compound tested. In addition to the comparison of the percent of cells 
demonstrating each response to baclofen application, the average 
percent change in the magnitude of sustained current was also 
compared back to the average percent change seen in hippocampal 
cultures isolated from 6–8 day old rats that were treated with baclofen 
in the absence of any kinase inhibitors or activators. 
Although over 12 different isoforms of PKC have been classified, 
broad-spectrum PKC inhibitors were used as a first step in determining 
the involvement of PKC in the signal transduction pathway of the 
enhancement of calcium current by GABAB receptor activation (for 
review see Tanaka and Nishizuka, 1994; Nishizuka, 1995; Webb et al., 
2000; Zarate and Manji, 2009). Several PKC inhibitors with different 
chemical structures were used for verification of the results. Each of 
the inhibitors used has been shown to be a potent and selective 
inhibitor of PKC. Since the same population of control cells was used 
for comparison with cells treated with various PKC and PKA 
inhibitors/activators, the initial statistical analysis was performed on a 
contingency table including the distribution of responses in the control 
population as well as the distribution of responses in the presence of 
each inhibitor or activator (P < 0.001, Chi-square test). The first PKC 
inhibitor tested was the PKC fragment 19–36, which corresponds to a 
conserved region of the regulatory domain of PKC. Since the PKC 
fragment 19–36 is not membrane permeable, it was included in the 
internal pipette solution. The distribution of the responses differed in 
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the presence of the PKC fragment 19–36 in comparison to the control 
cells (Fig. 3; P = 0.003 using a Chi-square). In control cultures 36.4% 
of the cells demonstrated an increase in sustained calcium current in 
response to 10 μM baclofen (N=44). When the PKC fragment 19–36 (2 
μM) was included in the recording pipette, there was a significant 
decrease in the percent of cells demonstrating an increase in sustained 
calcium current in response to 10 μM baclofen with only 7.4% of cells 
demonstrating an increase (N=27, P = 0.010 using a Fisher’s exact 
test for pairwise comparisons). The mean enhancement of the 
sustained current was only 6.7% in 2 out of 27 cells treated with the 
PKC fragment 19–36 and baclofen in comparison to the average 
enhancement of 19.0 ± 2.9% seen in 16 out of 44 cells treated with 
baclofen alone (Table 2). 
 
Figure 3 Effect of the PKC inhibitors, PKC fragment 19–36, GF-109203X, and 
chelerythrine chloride on the baclofen responses in hippocampal neurons. The 
sustained component of calcium current was measured at the end of a 300 ms 
depolarizing pulse to +10 mV from a holding potential of −80 mV. The bars represent 
the percent of cells demonstrating an increase in sustained calcium current in 
response to 10 μM baclofen. Data were collected from 44 control cells, 28 cells in the 
presence of the PKC fragment 19–36 (2 μM), 28 cells in the presence of GF-109203X 
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(500 nM), and 25 cells in the presence of chelerythrine chloride (5 μM). P = 0.003 
using a Chi-square when comparing all of the groups together. Pairwise comparisons 
were done with a Fisher’s Exact Test. * indicates a statistically significant difference. 
 
Table 2 Percent enhancement of sustained current magnitude with various kinase 
activators and inhibitors. 
The sustained component of calcium current was measured at the end of a 300 ms 
depolarization to +10 mV from a holding potential of −80 mV. Cells were treated with 
10 μM baclofen alone or in combination with various kinase inhibitors: PKC fragment 
19–36 (2 μM), GF-109203X (500 nM), chelerythrine chloride (5 μM), H-89 (1 μM), Rp-
cAMPS (30 μM), and PKA fragment 6–22 (500 nM). PKC and PKA were activated in the 
absence of baclofen by PMA (1 μM) and 8-Br-cAMP (500 μM), respectively. Data are 
given as mean ± sem when N>2. 
The PKC inhibitor, GF-109203X (also known as 
bisindolylmaleimide I and Gö 6850) was also used to determine the 
involvement of PKC in the signal transduction pathway of GABAB 
receptor enhancement of L-type calcium current. GF-109203X is a 
competitive inhibitor for ATP binding and is highly selective for PKC 
(Toullec et al., 1991; Martiny-Baron et al., 1993). Since GF-109203X 
is membrane permeable, the compound was included in both the 
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external bath calcium solution and in the baclofen solution. The 
distribution of the responses differed in the presence of GF-109203X 
(500 nM) in comparison to the control cells (P = 0.003 using a Chi-
square). Focusing on the enhancement of sustained current, 36.4% of 
the control cells demonstrated enhancement of sustained calcium 
current when treated with 10 μM baclofen, while only 3.6% of cells 
demonstrated enhancement of sustained calcium current treated with 
10 μM baclofen when GF-109203X was included in the external 
recording solution (Fig. 3; P = 0.001 using a Fisher’s exact test for 
pairwise comparison). Only a single cell out of the 28 cells recorded 
from demonstrated a 7.51% increase in sustained calcium current with 
baclofen application when GF-109203X (500 nM) was included in the 
recording solutions, which is lower than the average percent increase 
for the 16 control cells demonstrating enhancement (19.0 ± 2.9%; 
Table 2). 
The last PKC inhibitor used to investigate the involvement of 
PKC in the signal transduction pathway of GABAB receptor 
enhancement of L-type calcium current was chelerythrine chloride. 
Chelerythrine chloride is membrane permeable and therefore was 
included in both the external calcium solution and in the baclofen 
solution. The distribution of the responses differed in the presence of 
chelerythrine chloride (5 μM) in comparison to the control cells (P = 
0.003 using a Chi-square). Only 8.0% of cells demonstrated an 
increase in sustained calcium current in response to 10 μM baclofen in 
the presence of chelerythrine chloride, which was significantly lower 
than the percent of cells demonstrating an increase in sustained 
calcium current in response to 10 μM baclofen without kinase inhibitors 
in the recording solutions (N=25; Fig. 3; P = 0.011 using a Fisher’s 
exact test for pairwise comparisons). The 2 cells that demonstrated 
enhancement of sustained calcium current when treated with 10 μM 
baclofen in the presence of chelerythrine chloride exhibited an average 
percent increase of 11.2%, which is lower than the average percent 
increase of the 16 control cells that demonstrated enhancement in 
response to 10 μM baclofen (19.0 ± 2.9%; Table 2). 
In the presence of all three of the PKC inhibitors, PKC fragment 
19–36, GF-109203X, and chelerythrine chloride, baclofen caused a 
similar attenuation of current in a subset of cells as seen with baclofen 
alone, indicating that PKC was not involved in the attenuation of 
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current by baclofen (average attenuation ranged from 13.6% to 
22.0% in the presence of the inhibitors). All three PKC inhibitors 
blocked the ability of baclofen to enhance sustained calcium current in 
response to baclofen application. These data all support the hypothesis 
that PKC is involved in the pathway of L-type calcium current 
enhancement by GABAB receptor activation. 
3.4 Activation of PKC by PMA mimics the effect of 
baclofen to enhance sustained current 
If a novel or conventional PKC isoform is involved in the signal 
transduction pathway of L-type calcium current enhancement by 
GABAB receptors, activation of PKC with a phorbol ester should mimic 
the enhancement of sustained calcium current seen with baclofen 
application. The phorbol ester PMA is a non-selective, general PKC 
activator and has been shown to activate both the conventional and 
novel PKC isoforms, but not the atypical PKC isoforms (Riedel et al., 
1993a, 1993b; Goode et al., 1994; Shieh et al., 1995, 1996). The 
distribution of the responses differed when PMA (1 μM) was applied to 
cells in comparison to control cells where 10 μM baclofen was applied 
(P = 0.003 using a Chi-square). The distribution of responses differs 
between baclofen and PMA because PMA does not mimic the 
attenuation of calcium current seen with baclofen. There was only a 
single cell demonstrating a small decrease (8.74%) in response to PMA 
application, which suggests that the decrease of calcium current in 
response to GABAB receptor activation is not through a PKC mediated 
pathway (P = 0.003 using a Fisher’s exact test for pairwise 
comparisons). However, as seen with baclofen application, a third of 
the cells (30.8%) demonstrated enhancement of sustained calcium 
current when 1 μM PMA was applied to hippocampal cultures isolated 
from rat pups that were 6–8 days old (N=26; Fig. 4). The average 
percent increase of the 8 cells that demonstrated enhancement of 
sustained calcium current in response to PMA application was 21.7 ± 
5.2%, which is consistent with the 16 control cells that demonstrated a 
19.0 ± 2.9 % increase with 10 μM baclofen application (Table 2). 
Thus, the enhancement of sustained current is very similar whether 
the currents were measured in the presence of baclofen or PMA. The 
distribution of responses with PMA also appears very similar to that of 
baclofen in PTX treated cells (Fig. 1). PTX eliminated the effect of 
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baclofen on N-type calcium current allowing only the L-type calcium 
current response to remain intact. The response to PMA should be 
similar if activation of PKC only affects the L-type calcium channels 
and not N-type calcium channels. This experiment using the PKC 
activator PMA supports the hypothesis that PKC is involved in the 
signal transduction mechanism of L-type calcium current enhancement 
by GABAB receptors. 
 
Figure 4 Effect of the PKC activator PMA in hippocampal neurons. The sustained 
component of calcium current was measured at the end of a 300 ms depolarizing pulse 
to +10 mV from a holding potential of −80 mV. Cells were classified as demonstrating 
a decrease (black bar), no change (light gray bar), or an increase (dark gray bar) in 
response to 10 μM baclofen or 1 μM PMA. Data were collected from 44 cells with 
baclofen and 26 cells with PMA application (P = 0.003 using a Chi-square). Pairwise 
comparisons were done with a Fisher’s Exact Test. * indicates a statistically significant 
difference. 
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3.5 PKA inhibitors had varying effects on the 
enhancement of L-type current by GABAB receptors 
In addition to PKC, Shen and Slaughter (1999) showed that the 
PKA inhibitor, Rp-cAMP (membrane impermeable, included in the 
recording pipette; 50 μM), was able to suppress L-type calcium current 
enhancement by GABAB receptors in the salamander retina. Therefore, 
three different PKA inhibitors, Rp-cAMPS (membrane permeable form), 
H-89, and PKA fragment 6–22, as well as a PKA activator, 8-Br-cAMP, 
were used to address the involvement of PKA in the signal 
transduction pathway of L-type calcium current enhancement by 
GABAB receptor activation in rat hippocampus. 
In analyzing all three of the PKA inhibitors together and 
comparing the distribution with the control cells, there is a significant 
difference in the distribution of the responses to baclofen in the 
absence and presence of PKA inhibitors (Fig. 5; P = 0.002 using a Chi-
square). However, there were no significant differences in the 
percentage of cells demonstrating enhancement of sustained calcium 
current with 10 μM baclofen application when Rp-cAMPS (30 μM, 
N=25) was present (control = 36.4% and Rp-cAMPS = 16.0%; Fig. 5). 
The average enhancement of sustained current in the presence of Rp-
cAMPS (11.2 ± 0.65, N=4) was slightly lower than in control cells 
(Table 2). In contrast to Rp-cAMPS, the percent of cells demonstrating 
enhancement of sustained calcium current in response to application of 
baclofen differed significantly in the presence of H-89 (1 μM, N=28) in 
comparison to the control cells (3.6%; Fig. 5; P = 0.001 using a 
Fisher’s exact test for pairwise comparisons). This was similar to the 
results obtained with the PKA fragment 6–22, where only 6.1% of the 
cells demonstrated an enhancement of the sustained component of 
current when 500 nM PKA fragment 6–22 was included in the 
recording pipette (N=34). Thus, both H-89 and PKA fragment 6–22 
blocked the ability of baclofen to enhance L-type calcium current, but 
baclofen was still able to enhance sustained current in the presence of 
Rp-cAMPS. It is important to note that cells demonstrating an increase 
in sustained current in the presence of both H-89 and PKA fragment 6–
22 had increases of comparable magnitude to cells without any PKA 
inhibitors (H-89, 42.4%; PKA fragment 6–22, 22.9%; Table 2)). Thus, 
the data obtained with PKA inhibitors is inconclusive as to the role PKA 
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plays in sustained calcium current by the GABAB agonist baclofen. The 
attenuation of current by baclofen was not blocked since there was no 
significant difference in the magnitude of the attenuation in the subset 
of cells demonstrating attenuation when the PKA inhibitors were 
present in comparison to cells treated with baclofen alone (average 
attenuation ranged from 13.8% to 21.8% in the presence of the 
inhibitors). 
 
Figure 5 Effect of the PKA inhibitors, H-89, Rp-cAMPS, and PKA fragment 6–22 on 
the baclofen responses in hippocampal neurons. The sustained component of calcium 
current was measured at the end of a 300 ms depolarizing pulse to +10 mV from a 
holding potential of −80 mV. The bars represent the percent of cells demonstrating an 
increase in sustained calcium current in response to 10 μM baclofen. Data were 
collected from 44 control cells, 28 cells in the presence of H-89 (1 μM, P = 0.001), 25 
cells in the presence of Rp-cAMPS (30 μM, P = 0.100), and 34 with PKA fragment 6–
22 (500 nM, P=0.002). Pairwise comparisons were done with a Fisher’s Exact Test. * 
indicates a statistically significant difference. 
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3.5 8-Br-cAMP does not modulate calcium currents in 
the neonatal rat hippocampus 
To determine whether PKA activation mimics the modulatory 
effects of baclofen, the cell-permeable cAMP analogue 8-Br-cAMP was 
used. Initial experiments were performed with 1 mM (EC50 = 166μM; 
Ogreid et al., 1989). 8-Br-cAMP was applied to the cells the same way 
baclofen was applied. Out of 10 cells, 4 cells demonstrated a decrease 
in sustained current whereas 6 cells demonstrated no change in 
sustained current amplitude. No enhancement of sustained current 
was seen with this concentration. However, the cells did not tolerate 
this concentration well so that it was difficult to hold the cells through 
multiple applications and washes. Therefore subsequent experiments 
were performed with 500 μM 8-Br-cAMP. The distribution of the 
responses differed when 500 μM 8-Br-cAMP was applied to the cells in 
comparison to the control cells in which 10 μM baclofen was applied 
(Fig. 6; P < 0.001 using a Chi-square). Most of the cells (91.7%) 
demonstrated no effect in response to 500 μM 8-Br-cAMP application, 
suggesting that PKA is not involved in the signal transduction 
mechanism of either the enhancement of L-type calcium current or 
attenuation of N-type calcium current by GABAB receptor activation. 
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Figure 6 Effect of the PKA activator 8-Br-cAMP in hippocampal neurons. The 
sustained component of calcium current was measured at the end of a 300 ms 
depolarizing pulse to +10 mV from a holding potential of −80 mV. Cells were classified 
as demonstrating a decrease (black bar), no change (light gray bar), or an increase 
(dark gray bar) in response to 10 μM baclofen or 500 μM 8-Br-cAMP. Data were 
collected from 44 cells with baclofen and 24 cells with 8-Br-cAMP application (P < 
0.001 using a Chi-square). Pairwise comparisons were done with a Fisher’s Exact Test. 
* indicates a statistically significant difference. 
Section 4 - DISCUSSION 
The importance of calcium influx in neuronal function makes it a 
prime site for modulation by neurotransmitters and second 
messengers. Many inhibitory interneuron subtypes within the 
hippocampus utilize GABA to regulate the overall excitability of the 
hippocampus. Our laboratory has demonstrated that activation of 
GABAB receptors can enhance calcium influx through L-type calcium 
channels and attenuate calcium influx through N-type channels during 
development of the rat hippocampus (Carter and Mynlieff, 2004; Bray 
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and Mynlieff, 2009). Using calcium imaging, a similar enhancement of 
calcium current by GABAB receptor activation was recently reported in 
hippocampal neurons isolated from embryonic tissue (Park et al., 
2010). GABAB receptors are metabotropic and thus regulate various 
channels through activation of G-proteins. There are several 
mechanisms of calcium channel modulation through direct and indirect 
signaling pathways. One of the most common signaling pathways 
associated with GABAB receptor activation is through Gi/o proteins 
(Morishita et al., 1990; Campbell et al., 1993; Menon-Johansson et al., 
1993; Greif et al., 2000; Mannoury La Cour et al., 2008). Both N-type 
and P/Q-type calcium current inhibition generally occurs through direct 
modulation by Gβγ subunits that are sensitive to PTX suggesting the 
involvement of Gi/o proteins (Kleuss et al., 1991; Herlitze et al., 1996; 
Ikeda et al., 1996; Furukawa et al., 1998; Zamponi and Snutch, 1998; 
Kajikawa et al., 2001; Mirshahi et al., 2002). In the current study, 
treatment with PTX in hippocampal cultures isolated from 7 day old 
rats blocked the ability of baclofen to decrease calcium current, which 
has been shown to be through N-type calcium channels (Carter and 
Mynlieff, 2004). This is consistent with other studies that have 
demonstrated the involvement of Gi/o proteins in the attenuation of N-
type calcium current by GABAB receptor activation in other brain 
regions (Amico et al., 1995; Santos et al., 1995; Harayama et al., 
1998; Bertrand et al., 2003). The signal transduction mechanism of L-
type calcium current enhancement by GABAB receptors in the rat 
hippocampus is not known. Enhancement of L-type calcium current by 
GABAB receptors was still seen in the presence of PTX, indicating that 
Gi/o proteins are not involved in the signaling pathway of L-type 
current enhancement by GABAB receptors. 
L-type calcium channels have several consensus sites for 
phosphorylation by protein kinases, particularly PKC and PKA 
(Obenauer et al., 2003). Therefore, the involvement of both PKC and 
PKA in the GABAB mediated enhancement of L-type calcium current 
was investigated using inhibitors and activators for each kinase. 
Several broad-spectrum PKC inhibitors were used to verify the 
involvement of PKC. All three PKC inhibitors used, PKC fragment 19–
36, GF-109203X, and chelerythrine chloride blocked the ability of 
baclofen to enhance L-type current in hippocampal cultures isolated 
from neonatal rats. These PKC inhibitors were chosen based on their 
specificity to several if not all of the PKC isoforms, their cell 
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permeability, and their varying chemical structures. To confirm the 
involvement of PKC, a phorbol ester, PMA, was used to activate PKC 
and the effects on sustained calcium current were measured. 
Enhancement was observed with PMA application in approximately the 
same percentage of cells as with baclofen application. All of these data 
suggest that PKC is involved in the signal transduction pathway of L-
type calcium current enhancement by GABAB receptors in neonatal rat 
hippocampus. 
Involvement of PKC in the signaling pathway implies that 
activation of GABAB receptors is coupled to G-proteins known to 
activate phospholipase C such as the α subunit of those in the Gq 
family or the βγ subunit of Gi proteins (Camps et al., 1992; Clapham 
and Neer, 1997; Hansen et al., 2003; Murthy et al., 2004). The lack of 
effect of PTX treatment on L-type calcium current enhancement rules 
out the possibility that Gi is mediating the PKC effect. Mannoury La 
Cour et al. (2008) used an antibody-capture/scintillation proximity 
assay to investigate coupling between Gq/11 and GABAB receptors in the 
hippocampus. These data appear to be in contradiction with the 
activation of PKC by GABAB receptors. However, the coupling with Gq/11 
was the only G-protein in the Gq family tested in this study. There are 
three other distinct G-proteins, G14, G15, and G16 that may mediate this 
response and were not tested by Mannoury La Cour et al. (2008). In 
addition, the coupling of GABAB to Gi/o had an EC50 on the order of 
300–500 μM for GABA and ~50 μM for baclofen, which are significantly 
higher than values reported for GABAB receptor responses mediated by 
Gi/o (Dolphin and Scott, 1987; Harrison, 1990; Sodickson and Bean, 
1996). Shen and Slaughter (1999) reported that the PKC mediated 
enhancement of L-type current occurred with nanomolar 
concentrations of baclofen in the salamander retina. Experiments using 
calcium imaging to measure increases in intracellular calcium due to 
influx across voltage-dependent channels suggest that baclofen 
enhances L-type calcium current in the nanomolar range in our 
hippocampal cells, whereas attenuation of N-type calcium current 
requires higher concentrations (unbpublished). It is possible that the 
antibody-capture/scintillation proximity assay is not sensitive enough 
to demonstrate coupling at low concentrations of agonist. 
The data obtained with the PKA inhibitors and activator are 
more difficult to interpret. Two of the PKA inhibitors, H-89 and PKA 
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fragment 6–22, blocked the baclofen mediated enhancement of L-type 
current whereas a third type of inhibitor, Rp-cAMPS did not. There are 
a number of potential explanations for the variety of responses seen. 
Rp-cAMPS and H-89 inhibit PKA through two very different 
mechanisms. Rp-cAMPS prevents dissociation of the catalytic subunit 
from the regulatory subunit by competitively binding to the cAMP sites 
on the regulatory subunit. In comparison, H-89 associates with the 
ATP binding site on the catalytic subunit and blocks the 
phosphorylation processes of PKA. Although H-89 is a potent inhibitor 
for PKA (Chijiwa et al., 1990), it has been shown to inhibit several 
other kinases including, PKG (IC50 = 340 nM), Ca2+/calmodulin-
dependent protein kinase II (CaMKII; IC50 = 11 μM), and PKC (IC50 = 
14 μM; Davies et al., 2000; for review see Lochner and Moolman, 
2006). Thus, it is possible that H-89 is inhibiting other kinases causing 
variation in the calcium current responses with baclofen application 
when compared to Rp-cAMPS. However, the PKA fragment 6–22 
should be very specific to PKA with little effect on other kinases. 
The variability of the PKA inhibitor data is not in contradiction 
with studies in salamander retina. Shen and Slaughter (1999) 
demonstrated that GABAB receptor activation can lead to the 
enhancement of L-type calcium current in a subset of salamander 
retinal neurons. Approximately 43% of the cells they tested showed an 
enhancement of current in response to application of 500 nM baclofen. 
In their study, the enhancement of L-type current was blocked in the 
presence of the PKC inhibitors GF-109203X and PKC fragment 19–36. 
In comparison to the PKC inhibitors, the PKA inhibitor Rp-cAMP only 
partially suppressed the enhancement of L-type current. Their study 
suggested that PKC is more important than PKA in the signaling 
pathway of GABAB receptor modulation of L-type current in the 
salamander retina (Shen and Slaughter, 1999). Our data with the PKC 
activator PMA, suggest that activation of PKC alone is sufficient to 
enhance L-type calcium current. Direct activation of PKA with 8-Br-
cAMP did not result in the enhancement of L-type calcium current 
suggesting that activation of PKA alone is not sufficient to enhance L-
type calcium current. It is possible that activation of GABAB receptors 
activates both Gq to turn on PKC and Gs to turn on PKA. Since all PKC 
inhibitors blocked the enhancement and the PKC activator mimicked 
the enhancement, it is likely that PKC activation is necessary to 
enhance L-type calcium current in neonatal hippocampal neurons. The 
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inhibition by two of the PKA inhibitors may reflect a supportive role of 
PKA in this process, since the PKA activator alone was not sufficient to 
produce the response. PKA and PKC would lead to phosphorylation on 
different residues of the calcium channel and thus, it is possible that 
phosphorylation at the PKA site makes phosphorylation at the PKC site 
more likely but in and of itself, is not capable of enhancing the current. 
For example, current through TRPV4 channels is enhanced by 
phosphorylation of different residues by PKC and PKA (Fan et al., 
2009). Alternatively, there could be some interaction between the 
kinases prior to direct phosphorylation of the channel. Either kinase 
may not directly phosphorylate L-type calcium channels, but rather 
phosphorylate another intermediate effector protein or even each 
other. For example, in isolated rat ventricular myocytes activation of 
α1A adrenoceptors leads to enhancement of L-type current. This 
enhancement of L-type calcium current is mediated through a PKC and 
CaMKII pathway (O-Uchi et al., 2008). Thus, it is possible that PKC or 
PKA may phosphorylate and activate CaMKII to enhance L-type 
current in the rat hippocampus. Both the regulatory subunit of PKA 
and CaMKII β-subunit exhibit consensus sequences for PKC mediated 
phosphorylation, whereas PKC α and β both exhibit consensus 
sequences for PKA mediated phosphorylation (Obenauer et al., 2003). 
Although inhibitors of specific isoforms of PKC were not utilized 
in this study, the age of the pups and the specificity of PMA give some 
indication as to which isoforms may be involved. A study by Roisin and 
Barbin (1997), which explored the presence of several PKC isoforms 
during hippocampal development, suggests that PKCγ is likely not 
involved in the signaling pathway in this first postnatal week. PKCγ 
levels remain relatively low for the first postnatal week and only begin 
to rise following postnatal day 7. All of the other PKC isoforms tested, 
α, β, ε, and ζ were highly expressed by postnatal day 7. Therefore, 
each of these isoforms could be involved in the pathway of GABAB 
receptor mediated enhancement of L-type calcium current. Activation 
of PKC with PMA mimicked the enhancement seen with baclofen 
application, which suggests that either conventional or novel PKC 
isoforms are involved in the pathway rather than the atypical isoforms 
further reducing the potential PKC candidates to α, β, and ε. 
In conclusion, the current study has demonstrated that 
attenuation of N-type calcium current by GABAB receptor activation is 
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mediated through a PTX sensitive G-protein pathway (Gi/o) and does 
not involve either PKC or PKA. Enhancement of L-type calcium current 
was still observed in the presence of PTX, which demonstrated that Gi/o 
proteins are not involved in the pathway. Enhancement of L-type 
calcium current was not seen in the presence of PKC inhibitors and 
was observed with direct activation of PKC with a phorbol ester 
suggesting that PKC is involved in the pathway of L-type calcium 
current enhancement by GABAB receptor activation in the rat 
hippocampus. Enhancement was still observed in the presence of Rp-
cAMPS, but not in the presence of two other PKA inhibitors, H-89 or 
PKA fragment 6–22, suggesting that PKA may be involved in the 
response. However, direct activation of PKA with a cAMP analogue, 8-
Br-cAMP, did not result in the enhancement of L-type calcium current 
suggesting that activation of PKA alone is not sufficient to enhance L-
type calcium current. 
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